Keith S. Manchester - 24 May 2023 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role: Director
Signature: /s/ David C. Hastings as attorney-in-fact for Keith S. Manchester
Issuer symbol: ABUS
Transactions as of: 24 May 2023
Net transactions value: $0
Form type: 4
Filing time: 26 May 2023, 16:18:08 UTC
Previous filing: 14 Nov 2022
Next filing: 14 Sep 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABUS	Stock Option (Right to Buy)	Award	$0	+55,000		$0.000000	55,000	24 May 2023	Common Shares	55,000	$2.56	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on May 24, 2023, the date of the grant.
F2	The option is fully vested and exercisable as of the date of the grant.